Author: admin

  • Early Environmental Exposure Impacts Liver Epigenome

    Early Environmental Exposure Impacts Liver Epigenome

    You have often heard “You are what you eat,” but according to research from Baylor College of Medicine, the new phrase could be “You are what you are exposed to.” New research shows that, in animal models, the liver epigenome is permanently changed when exposed to certain chemicals in the environment early in life when the liver is developing, making the organism more vulnerable to diet-triggered metabolic dysfunction later in life. 

    The findings, published in Nature Communications, show how early life chemical exposure actually reprograms the liver epigenome, aging it more rapidly.

    “In our study, we found that even brief exposure to certain chemicals while the liver is developing prematurely aged the liver epigenome. Exposure to these endocrine-disrupting chemicals (EDCs) caused the young liver to acquire an adult epigenomic signature,” said Dr. Cheryl Walker, professor and director of the Center for Precision Environmental Health at Baylor and lead author on the study. “However, this premature aging of the epigenome did not have an effect on health until later in life and after exposure to a high-fat diet.”

    The epigenome is sometimes referred to as the “software” or “operating system” of the genome. It is comprised of small chemical modifications to DNA and the proteins that make up our chromosomes, and controls the activity of all the genes within the genome. During early life, as our organs develop, the epigenome guides and changes along with normal developmental milestones. Exposure to an EDC during this process can cause widespread reprogramming of this “software,” and this reprogramming persists for the life of the individual. Depending on the organ, the window of vulnerability for this reprogramming may be anytime from development in the womb to childhood and adolescence, depending on how long normal development lasts. 

    “In a healthy liver we see the epigemone go through a normal aging process. In our study, after exposure to an EDC, we were able to see this process accelerated. So a 6-day old rat had the same epigenome we would normally see in an adult rat,” said Walker, who also is the Alkek Presidential Chair in Environmental Health at Baylor. “The effect of this change on metabolic function wasn’t immediate; instead, it was like a ticking time bomb, which was only ignited when we switched the animals to a Western-style diet, high in fat, sugar and cholesterol.”

    Rats that were exposed early to EDC and later to a Western-style diet were found to be more susceptible to metabolic dysfunction than those that had the same EDC exposure, but were kept on a healthy diet. Those that remained on a healthy diet, despite the fact their epigenome had been reprogrammed, did not show the same changes in expression of genes that control metabolism, or accumulation of lipids in their serum, seen in rats on the high fat, sugar and cholesterol diet.

    “This study shows us how environmental exposures affect our health, and disease susceptibility, both early and later in life,” Walker said. “It also shows us that some people may be more adversely affected by a high-fat diet as adults than others due to environmental exposures they experienced earlier in their life.”

    Featured as the June paper of the month by the National Institute of Environmental Health Sciences (NIEHS), this work was supported as part of the NIEHS multi-phased Toxicant Exposures and Responses by Genomic and Epigenomic Regulators of Transcription (TaRGET) Program.  While these findings are only in lab models at this time, researchers hope this and similar studies being conducted by the TARGET II Consortium can lead the way to identifying biomarkers to help better predict who is at risk for metabolic dysfunction such as fatty liver disease, diabetes or heart disease, and allow for more precise and early interventions.  

    Others who contributed to the work include Lindsey S.Treviño, Jianrong Dong, Ahkilesh Kaushal, Tiffany A.Katz, Rahul Kumar Jangid, Matthew J.Robertson, Sandra L.Grimm, Chandra Shekar R. Ambati, Vasanta Putluri, Aaron R.Cox, Kang Ho Kim, Thaddeus D.May, Morgan R.Gallo, David D. Moore, Sean M. Hartig, Charles E.Foulds, Nagireddy Putluri, Cristian Coarfa. For affiliation please see the full publication in Nature Communications.

    This work was supported in part by NIH grants U01ES026719, 1P30ES030285, andR01ES023206 to CLW, American Diabetes Association grant #1-18-IBS-105 and NIH grant R01DK114356 to S.M.H., and a sub-award from NIH grant U24DK097748 to C.E.F. Lipidomics and metabolomics sample processing and analysis were conducted by the Metabolomics Core at Baylor College of Medicine, supported by CPRIT Proteomics and Metabolomics Core Facility funding (RP170005), the NIH (P30 CA125123), and the Dan L Duncan Cancer Center at Baylor College of Medicine. 

  • NIH Statement on World Asthma Day 2020

    NIH Statement on World Asthma Day 2020

    Today on World Asthma Day, the National Institutes of Health stands with patients, families, advocates, researchers, and health care professionals to raise awareness about this common chronic respiratory disease, the people it affects, and the biomedical research that improves its prevention and treatment.

    Asthma is a chronic lung disease that causes periods of wheezing, chest tightness, shortness of breath, and coughing. It is a major contributing factor to missed time from school and work, with severe attacks requiring emergency room visits and hospitalizations. Sometimes these asthma attacks can be fatal.

    This year, we recognize that the coronavirus disease 2019 (COVID-19) pandemic is creating concern and uncertainty for many people around the globe, including those with asthma. The disease can affect the nose, throat, and lungs, cause an asthma attack, and possibly lead to pneumonia and acute respiratory disease. According to the Centers for Disease Control and Prevention, people with asthma should continue their current asthma medications and discuss any concerns with their healthcare provider. Researchers at NIH and elsewhere are working to learn more about COVID-19 and to develop specific treatments and vaccines.

    Three NIH institutes support and conduct studies on asthma — the National Institute of Environmental Health Sciences (NIEHS); the National Heart, Lung, and Blood Institute (NHLBI); and the National Institute of Allergy and Infectious Diseases (NIAID). Institute scientists and grantees made several important advances in understanding, treating, and managing asthma in 2019. These findings and other highlights are featured in five topic areas below:

    • Relationship between asthma and COVID-19
    • Populations at risk of developing asthma
    • Potential new treatments
    • Genes involved in asthma
    • Asthma management

    Relationship between asthma and COVID-19

    NIAID is initiating a home-based study to assess the incidence of infection with SARS-CoV-2, the virus that causes COVID-19, in children and their caregivers and siblings. A key objective of this observational study will be to determine if infection rates or immune responses to SARS-CoV-2 infection differ in children who have asthma or other allergic conditions compared to those who have not been diagnosed with or treated for these conditions.

    NIAID also is starting an observational study in patients hospitalized for COVID-19 to understand if specific characteristics of the immune response influence or reflect the severity of infection. This study may help determine whether underlying diseases, such as asthma, influence the body’s response to SARS-CoV-2 infection.

    Populations at risk of developing asthma

    Children

    NIH scientists are making progress in understanding the underlying factors that contribute to the development of asthma in U.S. children. This year, an international collaboration led by NIEHS scientists reported that the presence of newly discovered novel epigenetic markers — or chemical tags that attach to DNA — may indicate a newborn’s risk of developing asthma. The data were generated by the Pregnancy and Childhood Epigenetics Consortium and may help researchers find asthma biomarkers, or molecular indicators of asthma, and identify at birth which children will eventually develop the condition.

    At NHLBI, researchers discovered a link between childhood asthma flare ups and changes in the lung microbiome, the communities of bacteria and other microorganisms that are normally present in the lung and usually do not cause symptoms. The scientists determined that children with mild to moderate asthma who experienced early signs of an upcoming asthma flare up tended to have higher levels of certain types of disease-causing bacteria in their lungs. The study could lead to a precision medicine approach for treating mild to moderate childhood asthma by altering the number and types of bacteria in a child’s airways.

    Ongoing NIAID-funded clinical studies focus on interventions to prevent asthma development in children at high risk of developing the condition. One team of researchers studied a large group of children who were hospitalized as infants with bronchiolitis, a common early-life lung infection usually caused by a virus. The scientists found that recurrent wheezing by age 3 is at least three times more likely to occur in children whose bronchiolitis was associated with a rhinovirus C infection and who also had early signs of allergy to foods or inhaled allergens.

    African Americans and people of African ancestry

    Another group that bears a disproportionate burden of asthma is African Americans. In an NHLBI-funded study that is the largest genome-wide association study of asthma in African ancestry populations to date, researchers identified two novel regions on a specific chromosome that may be linked to asthma risk. The scientists theorize that a better understanding of the genetic risk factors for asthma in African ancestry populations will lead to development of better therapeutic interventions.

    Potential new treatments

    Using a mouse model of asthma, NIEHS researchers reported a possible treatment for neutrophilic asthma, a particularly severe form that responds poorly to the standard asthma therapy of corticosteroids. The orally available drug VTP-938 made it easier for the mice to breathe after they were exposed to house dust extracts. The results suggest that VTP-938 may be an innovative treatment for humans with this steroid-resistant form of asthma.

    Genes involved in asthma

    An NIAID-funded study sought to understand why some, but not all, colds lead to asthma attacks among children with asthma. The scientists obtained nasal washings from 106 children with severe asthma who experienced cold symptoms. Members of the research team compared samples from those who required corticosteroids after a cold-induced asthma attack and those who did not have an asthma attack following a cold. The research team found that colds that led to an asthma attack caused changes in the production of six families of genes that are associated with maintaining the function of the outermost layer of tissue lining the respiratory tract and with the responses of immune cells in close contact with this layer.

    Variations in two genes — the aryl hydrocarbon receptor nuclear translocator (ARNT) and the protein tyrosine phosphatase, nonreceptor type 22 (PTPN22) — are associated with immune-mediated diseases, such as asthma, in several ethnicities, according to NIEHS researchers and their collaborators. Because ARNT and PTPN22 are sensitive to environmental factors, this study is the first to demonstrate across ethnicities the combined role of these genes and environmental changes in the development of immune-related conditions like asthma.

    Asthma management

    NHLBI’s National Asthma Education Prevention Program is coordinating the 2020 focused updates to the 2007 Asthma Management Guidelines. These guidelines are designed to improve the care of people living with asthma as well as help primary care providers and specialists make decisions about asthma management. NHLBI released the updated focus areas of the guidelines for public comment, and the final recommendations for these areas are expected to be published later this year. They will address several priority topic areas listed below:

    • Using inhaled medications when needed
    • A new type of inhaled medication called long acting muscarinic antagonists
    • Treating allergies by exposure to low doses of allergens by mouth or with shots
    • Reducing indoor asthma triggers
    • A new procedure for asthma known as bronchial thermoplasty
    • A fractional exhaled nitric oxide test that may be helpful in diagnosing or managing asthma

    Experts hope that these guidelines will help reduce the burden of asthma nationwide and improve the quality of life for those living with the condition.


    About the National Heart, Lung, and Blood Institute (NHLBI): NHLBI is the global leader in conducting and supporting research in heart, lung, and blood diseases and sleep disorders that advances scientific knowledge, improves public health, and saves lives. For more information, visit www.nhlbi.nih.gov.

    About the National Institute of Allergy and Infectious Diseases (NIAID): NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.

  • Commonly Used Chemicals Associated With Miscarriage, Yale School of Public Health Study Finds

    Commonly Used Chemicals Associated With Miscarriage, Yale School of Public Health Study Finds

    Exposure to synthetic chemicals widely used in food packaging, such as pizza boxes, and commonly found in drinking water supplies is associated with a woman’s risk for miscarriage in the second trimester, a new Yale School of Public Health study finds.

    Credit: Dreamstime

    Researchers at the Yale School of Public Health have found that maternal exposure to synthetic chemicals widely used in food packaging and commonly found in drinking water supplies is associated with a woman’s risk for miscarriage in the second trimester.

    All women in the Danish cohort studied had detectable and multiple types of per- and polyfluoroalkyl substances (PFAS) in their pregnancy serum. The study estimated a nearly 80% to 120% increased risk for miscarriage in women with the highest level of two common PFAS compounds, compared with those in the cohort with the lowest PFAS levels. Some positive associations, though in smaller magnitudes and less consistent, were also reported for exposure to other types of PFAS compounds evaluated.

    The association was stronger among women who had already borne children, and the researchers said that the results need to be replicated. The study is published in the journal Environmental Health Perspectives.

    PFAS, introduced in the 1940s, are widely used in the manufacture of everyday products around the globe — from cookware, to clothing, carpets, and firefighting foam. PFAS are also used in industries such as aerospace, automotive, construction, electronics, and the military. Production of the two most common types of PFAS has been phased out by U.S. manufacturers over concerns about the impacts on the environment and human health, but other compounds in the PFAS family are being produced as replacements. PFAS usage in commercial products is not currently regulated in the United States.

    “Policy regulation of PFAS exposure should consider adverse effects on maternal and child health, which have repeatedly suggested that these are vulnerable populations that need to be protected from exposure to these widespread chemicals,” said Zeyan Liew, the study’s lead author and an assistant professor in the department of Environmental Health Sciences at the Yale School of Public Health.

    “More studies should follow up to investigate whether PFAS, widespread pollutants that are affecting nearly all pregnancies in the general population, are a modifiable risk factor for miscarriage,” he said. Miscarriage is rather common and affects about 10% to 20% of all clinically recognized pregnancies.

    More studies should follow up to investigate whether PFAS, widespread pollutants that are affecting nearly all pregnancies in the general population, are a modifiable risk factor for miscarriage.

    Previous toxicological studies have suggested that high doses of PFAS exposure can cause pregnancy loss and infant deaths in rodents. However, whether PFAS exposure affects the risk of miscarriage in the general population was unclear. This is the largest epidemiological study based on pregnant women enrolled in the Danish National Birth Cohort and compared 220 women who carried their pregnancies through birth with 220 who experienced a miscarriage in the second trimester.

    Maternal serum samples were collected in early gestations (around week eight) in the cohort, where the researchers measured the serum-level of several common PFAS compounds in these women. The PFAS exposure level in this pregnancy cohort in Denmark is similar to the exposure level reported in the studies of U.S. general population.

    “Mechanistic studies are needed to elucidate the possible biological mechanisms that explain these associations,” Liew said. “Moreover, larger epidemiological studies are needed to replicate our findings, evaluate the possible threshold or dose-dependent effects of PFAS exposure on pregnancy loss, and address confounding by pregnancy history.”

    The cost for serum-PFAS measurement in the Danish cohort was funded by the Augustinus foundation. Liew was supported by the NIH/NIEHS Pathway to Independence Award.

    Article outro

    Author

    Explore More

    Featured in this article